These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


280 related items for PubMed ID: 11268330

  • 21. Autologous hematopoietic stem cell transplantation for severe autoimmune disease with special reference to rheumatoid arthritis.
    Tyndall A, EBMT/EULAR International Data Base. European Group for Blood and Marow Transplantation and European League Against Rheumatism.
    J Rheumatol Suppl; 2001 Oct; 64():5-7. PubMed ID: 11642506
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 25. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    Claxton DF, Ehmann C, Rybka W.
    Br J Haematol; 2005 Jul; 130(2):256-64. PubMed ID: 16029454
    [Abstract] [Full Text] [Related]

  • 26. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 27. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 28. Autologous hematopoietic stem cell transplantation for autoimmune diseases.
    Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D, Andolina M, Arnold R, Carreras E, Finke J, Kötter I, Kozak T, Lisukov I, Löwenberg B, Marmont A, Moore J, Saccardi R, Snowden JA, van den Hoogen F, Wulffraat NM, Zhao XW, Tyndall A, Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant; 2005 May; 35(9):869-79. PubMed ID: 15765114
    [Abstract] [Full Text] [Related]

  • 29. [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: "minitransplant"].
    Gómez-Almaguer D, Ruiz-Argüelles GJ, González-Llano O, Ruiz-Argüelles A, Cantú-Rodríguez OG.
    Gac Med Mex; 2002 May; 138(3):235-9. PubMed ID: 12096391
    [Abstract] [Full Text] [Related]

  • 30. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 31. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, Freiberg-Richter J, Röllig C, Geissler G, Lutterbeck K, Oelschlagel U, Ehninger G.
    Clin Cancer Res; 2001 Aug 01; 7(8):2254-62. PubMed ID: 11489799
    [Abstract] [Full Text] [Related]

  • 32. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Aug 01; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 33. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
    Petri M, Jones RJ, Brodsky RA.
    Arthritis Rheum; 2003 Jan 01; 48(1):166-73. PubMed ID: 12528116
    [Abstract] [Full Text] [Related]

  • 34. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
    di Grazia C, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G, Bregante S, Dominietto A, Mordini N, Bruno B, Frassoni F, Bacigalupo A.
    Haematologica; 2001 Jun 01; 86(6):646-51. PubMed ID: 11418375
    [Abstract] [Full Text] [Related]

  • 35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 36. Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease.
    Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, Black C, Durez P, Finke J, Forman S, Fouillard L, Furst D, Holmes J, Joske D, Jouet J, Kötter I, Locatelli F, Prentice H, Marmont AM, McSweeney P, Musso M, Peter HH, Snowden JA, Sullivan K, Gratwohl A.
    Bone Marrow Transplant; 1999 Oct 01; 24(7):729-34. PubMed ID: 10516675
    [Abstract] [Full Text] [Related]

  • 37. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B, Bahci S, Meisel R, Troeger A, Schönberger S, Laws HJ, Kramm C, Wessalowski R, Koscielniak E, Dilloo D, Göbel U.
    Klin Padiatr; 2007 Oct 01; 219(6):318-22. PubMed ID: 18050041
    [Abstract] [Full Text] [Related]

  • 38. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD, Goldberg SL, Pecora AL, Hsu JS, Brecher BA, Butrin L, Kobbe K, McKiernan P, Preti R.
    Biol Blood Marrow Transplant; 2004 Nov 01; 10(11):784-93. PubMed ID: 15505609
    [Abstract] [Full Text] [Related]

  • 39. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb 01; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 40. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC.
    Am J Hematol; 2001 Apr 01; 66(4):241-4. PubMed ID: 11279633
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 14.